Cartesian Therapeutics reported a net loss of $(77.4) million for the full year ended December 31, 2024, with total revenue of $38.913 million. The company ended the year with approximately $214.3 million in cash, cash equivalents, and restricted cash, which is expected to support operations into mid-2027.

Cartesian Therapeutics reported cash, cash equivalents, and restricted cash of approximately $104.8 million as of March 31, 2024. Net loss was $(56.8) million, or $(10.50) per share.

Cartesian Therapeutics reported its full year 2023 financial results, highlighting a pro forma cash balance of $118.3 million as of December 31, 2023, expected to fund operations into the second half of 2026. The company is advancing its pipeline with key milestones anticipated, including topline data from the Phase 2b study of Descartes-08 in myasthenia gravis expected mid-2024 and initiation of a Phase 2 study of Descartes-08 in systemic lupus erythematosus in 1H24.